Navigation Links
Unilife Realigns Operations to Drive Sales and Support Commercial Production of Unifill Syringes
Date:4/5/2011

YORK, Pa., April 5, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced it has commenced a scheduled realignment of its operating infrastructure in preparation for the upcoming full commercial production and sale of its innovative drug delivery devices to healthcare and pharmaceutical customers. This realignment is being led by Unilife's Chief Operating Officer, Dr. Ramin Mojdeh.

The adoption of these business efficiencies is expected to improve Unilife's cash flow and extend cash reserves by over $12 million during calendar year 2011. Through the elimination or deferral of expenditures no longer required at this time, Unilife expects to reduce operating expenses by approximately $5 million during calendar year 2011, and streamline capital spending programs to further improve cash reserves by approximately $7 million during calendar year 2011. These adopted changes will better enable Unilife to efficiently focus cash resources on the production and sale of the Unifill® prefilled syringe, the Unitract® 1mL syringe, and the commercialization of other pipeline products.

Over the last two years, Unilife significantly expanded its operational capabilities in order to meet the anticipated production requirements and stringent quality assurance expectations of current and prospective pharmaceutical customers. This operational surge by Unilife included the rapid expansion of its workforce to 150 staff, significant investment in new capital equipment, and the development of a state-of-the-art manufacturing facility in York, PA. As a result of this upfront investment, Unilife has successfully completed all quarterly milestones under the industrialization program for the Unifill syringe since July 2008, culminating in initial production of the product commencing last week, approximately nine months ahead of the original schedule.

Having met this key business milestone, the scheduled realignment now taking place will reduce operational expenditures, better position the Company to initiate the sale of the Unifill syringe to its existing pharmaceutical customer, and help finalize discussions with additional interested parties.

In addition to the elimination of a number of redundant positions across various levels of the organization, Unilife is strengthening and expanding its sales and marketing team to support the more rapid development of commercial relationships with a wider range of healthcare and pharmaceutical companies. A portion of the operational savings will also be redirected to support the continued development of an expanding device portfolio. Unilife expects that as a result of this realignment, it could be in a position to secure development, industrialization or exclusivity agreements with interested pharmaceutical parties that can support the commercialization of some of these pipeline products during the second half of 2011.

Dr. Mojdeh, said, "Having completed the key industrial milestone of initial Unifill syringe production well ahead of schedule, Unilife can implement a planned realignment of its business structure to better service the needs of pharmaceutical customers and deliver value to shareholders. In addition to strengthening our sales and marketing team and increasing our investments in R&D, we are streamlining other areas of our Company to improve cash flow and operational efficiencies. Unilife is uniquely positioned to service the acute needs of pharmaceutical companies that are seeking innovative, customized device solutions for their therapeutic drugs from a full-service partner that is agile, responsive and efficient in its business practices. By introducing these measures, we will accelerate our go-to-market strategy while strengthening our financial profile."

About Unilife CorporationUnilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator-controlled needle retraction features which are fully integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485-certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):Todd Fromer / Garth RussellKCSA Strategic CommunicationsP: + 1 212-682-6300Stuart FineCarpe DM IncP: + 1 908 469 1788Investor Contacts (Australia)Jeff CarterUnilife CorporationP: + 61 2 8346 6500
'/>"/>

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
2. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
3. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
4. Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe
5. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
6. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
7. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
8. Unilife Corporation Announces Financial Results for Fiscal Year 2011 First Quarter
9. Unilife Completes A$23.1 Million Private Placement
10. Unilife Corporation Moves into New State-of-the-Art Manufacturing Facility and Global Headquarters
11. Unilife Receives SPP Applications Exceeding A$12.8 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. The ... around 1.8% over the next decade to reach approximately $12.8 billion by ... and forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... YORK , February 23, 2017 ... its report on the global market for intraoperative ... be presently valued at US$ 513.9 million. According ... will keep surging on the grounds of increasing ... in the field of diagnostic imaging for neurosurgeries. ...
(Date:2/23/2017)... -- LG Innotek today announced that the company has developed the ... performance is 1.5 times higher than the competitor,s 45mW module. ... range of 200 -- 280nm, allowing it to be used for sterilization ... LG Innotek,s product emits UV in the range of 280nm. ... Until now, UV-C LED ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... leadership , media relations, content marketing, social media management, corporate communications, SEO and ... in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will ...
(Date:2/23/2017)... Angeles, California (PRWEB) , ... February 23, 2017 ... ... Global Sports Development will host a diverse symposium on “Doping in ... of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... announced today that it will soon begin franchising throughout the U.S. starting this ... to help bring the practice of meditation mainstream. Current Meditation will be the ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
Breaking Medicine News(10 mins):